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Cardiovascular disease is the leading cause of death in the general population; traditional risk factors seem inadequate to explain
completely the remarkable prevalence of cardiovascular mortality and morbidity observed in the uremic population. A role
for chronic inﬂammation has been well established in the development of atherosclerotic disease, and, on the basis of these
observations, atherosclerosis might be considered an inﬂammatory disease. Inﬂammation has been implicated in the etiology
of coronary artery disease in the general population, and traditional inﬂammatory biomarkers such as C-reactive protein (CRP)
and interleukin-6 (IL-6) have been shown to predict cardiovascular events in both symptomatic and asymptomatic individuals as
well as those in the uremic population. Later on, new nontraditional markers were related to the risk of cardiovascular morbidity
and mortality in general and in uremic population. As a consequence of the expanding research base and availability of assays, the
number of inﬂammatory marker tests ordered by clinicians for cardiovascular disease (CVD) risk prediction has grown rapidly
and several commercial assays have become available. So, up to now we can consider that several new nontraditional markers
as CD40-CD40 ligand system and pentraxin-3 seem to be signiﬁcant features of cardiovascular disease in general and in ESRD
population.
1.Introduction
Patients with end-stage kidney disease undergoing chronic
hemodialysis (HD) present higher mortality rates compared
with the general population. Once patients are on HD, the
risk of cardiovascular death is approximately 30 times higher
than that in the general population and remains 10–20 times
higher after stratiﬁcation for age, gender, and the presence of
diabetes. About half of the deaths of patients on dialysis are
attributed to cardiovascular causes including coronary heart
disease, cerebrovascular disease, peripheral vascular disease,
and heart failure.
End-stage renal disease (ESRD) patients suﬀer from a
state of chronic inﬂammation leading to cardiovascular
complications, progressive malnutrition, and death [1, 2].
Inﬂammation is subclinical, and chronic disorders of the
cytokine system or acute-phase proteins may be observed as
the sole evidence of a proinﬂammatory disorder.
According to this hypothesis traditional inﬂammatory
biomarkers such as tumor necrosis factor-alfa (TNF-alfa),
C-reactiveprotein(CRP),andinterleukin-6(IL-6)havebeen
shown to predict cardiovascular events in both symptomatic
and asymptomatic individuals as well as those in the ure-
mic population. More recently, several new nontraditional
biomarkers have been introduced in the clinical practice.
2. TraditionalBiomarkersof
ChronicInﬂammation
Low-grade chronic inﬂammation, as indicated by levels of
high-sensitivity C-reactive protein (hs-CRP), prospectively
deﬁnes the risk of atherosclerotic complications, adding
to the prognostic information provided by traditional risk
factors. The study of Ridker et al. [3] provides convinc-
ing evidence that, in apparently healthy subjects, baseline2 International Journal of Inﬂammation
serum levels of hs-CRP are predictive of future myocardial
infarction and ischemic stroke. Subsequent meta-analysis of
prospective population-based studies has compared patients
in the lower tertile of hs-CRP with those in the upper
tertile [4, 5]. With a good consistency between studies, a
higher risk for major coronary events was observed for the
upper tertile with the lowest tertile used as a reference. In
general population most studies showed a dose-response
relationship between the level of hs-CRP and risk of incident
coronary disease. Recent papers also suggest association with
incidence of sudden death [6, 7] and peripheral arterial
disease [8]. Through stratiﬁcation or multivariable statistical
adjustment, hs-CRP retains an independent association
with incident coronary events after adjusting for age, total
cholesterol, HDL cholesterol, smoking, body mass index,
diabetes, history of hypertension, exercise level, and family
history of coronary disease [9, 10]. In terms of prediction of
recurrent CVD events and death, the strongest association
with prognosis has been with hs-CRP; hs-CRP consistently
predicts new coronary events in patients with unstable
angina and acute myocardial infarction [11–20].
As elevated serum levels of hs-CRP have been shown
to be such a strong predictor of cardiovascular mortality
in the general population, available data suggest that the
association between inﬂammation and atherosclerosis is
particularlystronginuremicpatients[21,22].Zimmermann
et al. [2] reported that chronic inﬂammation enhances
cardiovascular risk and mortality; a few years later Ikizler et
al. [23] in a prospective study assessed the importance of hs-
CRP values as independent determination of hospitalization
in chronic hemodialysis (HD) patients.
Recently, it has been shown that proinﬂammatory
cytokines such as IL-6 may exert a direct inﬂammatory eﬀect
on the heart and peripheral circulation [24]. In a previous
published paper, we investigated the joint predictive power
of CRP and IL-6, in order to ascertain what is the prognostic
information that each index carries independently of the
other.Tothisaim,IL-6andCRPplasmalevelsweremeasured
in a cohort of 218 ESRD patients from diﬀerent centres
over a 4-year followup. Main outcomes were cardiovascular
and total mortality. This study showed that plasma IL-6
rather than CRP better predicts outcome in ERSD patients.
Various possible explanations may underline the advantage
of IL-6 over CRP as an outcome predictor. One possibility is
that, being located upstream in the cascade of events which
lead to the synthesis of many acute-phase reactants, IL-6 is
a better marker of the inﬂammatory burden aﬀecting the
development of cardiovascular disease. Another possibility
is that levels of IL-6 vary less than those of CRP, leading
to a more accurate classiﬁcation of patients at risk when
one single sample is taken. Finally, the toxic eﬀects of IL-6
on the heart and peripheral vasculature might be stronger
than those of CRP [24] .T h i ss t u d yp r o v i d e ss o m ei m p o r t a n t
implications. First, it gives further support to the hypothesis
about the role of inﬂammatory mediators in the genesis of
cardiovascular disease in dialysis patients [25–27]. Secondly,
it provides evidence suggesting the use of IL-6 in addition to,
or even in place of, CRP for the identiﬁcation of patients at
risk.
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Figure 1: Prognostic value of CD40L in the RISCAVID population.
Zhang et al. [28] reported that there was no association
between CRP haplotypes and cardiovascular outcome in
dialysis patients; this study argues against CRP as a cardio-
vascular risk factor. On the other hand, because variations
within the IL-6 gene were shown to aﬀect the risk for CVD
in a multiethnic dialysis cohort [29], this suggests that IL-6
should be the target for interventional studies.
According to these data, we suggest that all traditional
risk factors for death should be measured accurately in
uremicpatients.Clinicaleventsshouldbeidentiﬁedprospec-
tively, and, whenever possible, IL-6 levels should be mea-
sured repeatedly during the course of followup.
TNF-alfa, a proinﬂammatory cytokine (17kDa) origi-
nally associated with killing of tumor cells, has a pivotal
role in regulating both pro- and anti-inﬂammatory medi-
ators. TNF-alfa has been regarded a “master regulator” of
the cytokine cascade that provides a rapid form of host
defense against infection but is fatal in excess. TNF-alfa
is highly multifunctional with eﬀects on lipid metabolism,
coagulation, insulin resistance, and endothelial dysfunction.
The major cellular origin of TNF-alfa, previously known
as cachectin, is activated macrophages. It should be noted
that, whereas IL-6 is strongly associated with CRP and other
inﬂammatory biomarkers, the association between TNF-alfa
and CRP is rather weak. This suggests that circulating levels
may be inﬂuenced by a number of diﬀerent factors and that
circulating TNF-alfa levels may not reﬂect biologic activity
at the tissue levels. Although available evidence suggests
upregulated TNF-alfa system activity in ESRD patients [30],
data linking elevated circulating TNF-alfa levels to CVD and
mortality have not been as clear as for IL-6.
3. Nontraditional Biomarkers of
ChronicInﬂammation
It is now generally accepted that CD40-CD40 ligand interac-
tion is a main determinant of the proatherogenic phenotype
[31]. Originally identiﬁed in B and T lymphocytes as beingInternational Journal of Inﬂammation 3
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Figure 2: Acute phase of inﬂammation.
involved in T-cell-dependent B-cell activation and diﬀeren-
tiation, the CD40-CD40 ligand system has been implicated
in the pathophysiology of several chronic inﬂammatory
diseases including risk factor-related vascular damage [32].
CD40, a 50kDa integral membrane protein of the tumor
necrosis factor receptor family, and its cognate agonist CD40
ligand also known as CD154, a transmembrane 39-kDalton
protein structurally related to tumor necrosis factor-alpha,
are coexpressed by several cells of the vasculature, including
endothelial cells, smooth muscle cells, and macrophages
[31]. CD40 ligand also occurs in a soluble form (sCD40L)
that is considered to possess a full biological activity [33].
Increased sCD40L levels have been described in obesity [34],
hypercholesterolemia [35], diabetes [36, 37], and unstable
angina [38]. Furthermore, it has been recently reported
that circulating sCD40L has a strong independent prognos-
tic value among apparently healthy individuals [39]a n d
patients with acute coronary syndromes [40]a n dr e p r e s e n t s
an independent predictor of restenosis after percutaneous
transluminal angioplasty [41]. Thus, the clinical association
between soluble CD40L and cardiovascular events suggests
that soluble CD40L function spans the time interval from
early atherogenesis to late thrombotic complications.
According to this, Hocher et al. [42] recently demon-
strated during a follow-up period of 52 months that sCD40L
is an independent predictor of atherothrombotic events in
patients on HD. More recently we expanded on this topic
demonstrating that the prognostic value of sCD40L is
evident also in over 200 chronic HD patients from
the RISCAVID population at 24-month followup [43]
(RISCAVID, “risk cardiovascular in dialysis” is a prospective
observational study performed on a large HD population in
the northwestern region of Tuscany, Italy) (Figure 1).
In this paper we were able to demonstrate that this
prognostic value of sCD40L is already evident at 24 months
followup thus reinforcing the strong link between sCD40L
and clinical outcomes in patients in HD and suggesting a
possible clinical use of this new promising biomarker to
better deﬁne cardiovascular prognosis in these patients. The
striking prognostic impact of sCD40L on the clinical course
in patients in HD raises questions about the origin of this
biomarker. Platelets represent the main source of circulating
sCD40L in patients with acute coronary syndrome [38]a n d
in hypercholesterolemia [35]. Accordingly, plasma levels of
sCD40L correlate closely with markers of platelet activation
in these patient populations [35, 38]. Thus, increased circu-
lating levels of sCD40L might reﬂect an enhanced platelet
activationinHD.Accordingtothis,ithasbeendemonstrated
that circulating activated platelets (P-selectin/CD63-positive
platelets) are higher in HD patients than in controls and
further increase during HD sessions [44]. Potential causes
of such activation include possible stimulation of platelets
by proinﬂammatory cytokines that have been reported to
be increased in patients with end-stage renal disease [45].
Furthermore, the increased lipid peroxidation that has been
found in patients with chronic renal failure might also4 International Journal of Inﬂammation
participate in activating platelets [46]. On the other hand,
the lack of any correlation between circulating levels of
sCD40L and CRP seems to exclude a role for this platelet-
activating inﬂammatory biomarker [47] in the enhanced
sCD40L signaling observed in our study population.
Pentraxinisafamilyofproteinsconsideredtobemarkers
of the acute-phase inﬂammation [48, 49]( Figure 2). Cur-
rently, the pentraxin protein family is divided into two
subfamilies based on size: the classical “short” pentraxin
(25kDa) and the “long” pentraxin (40–50kDa). Pentraxin 3
(PTX3) is a “long” pentraxin that is highly expressed in the
heart, whereas C-reactive protein (CRP) is a “short” pen-
traxin and is produced from the liver [50]. PTX-3 expression
occurs in a variety of cell types, including endothelial cells,
mononuclear phagocytes, dendritic cells, smooth muscle
cells, ﬁbroblasts, adipocytes, and epithelial cells in response
to inﬂammatory cytokines and Toll-like receptor engage-
ment [51–53]. In several recent studies [54, 55]P T X 3
appeared to be not only an early indicator of irreversible
myocyte injury but also a prognostic marker in patients with
acute myocardial infarction. Latini et al. [56] reported the
acute-phase protein PTX3 as a predictor of 3-month mortal-
ity after adjustment for major risk factors and other acute-
phase prognostic markers. In a recently published paper of
Barbuietal.[57],the role ofPTX3 as a prognostic biomarker
was shown by an increased serum PTX3 that was closely
related to death due to MI, in-hospital or to 6 months, in
ACS patients, including STEMI, NSTEMI, and UAP groups.
More recently, Suliman et al. [58] analyzed plasma PTX-3
concentrations in relation to comorbidities (Davies score),
protein-energy wasting (PEW), and inﬂammation markers
in 200 prevalent HD patients, aged 64 ± 14 years, who had
been on HD treatment for a median period of 36 months.
Survival(42months)wasanalyzedinrelationtoPTX-3levels
(high PTX-3 tertile versus two lower tertiles). This study
shows that high levels of PTX-3 were found in prevalent HD
patients with CVD and PEW; furthermore, a powerful asso-
ciation of PTX-3 with comorbidities was founded. As PTX-3
predicts mortality independent of age and comorbidities in
prevalent HD patients, further designed studies addressing
the clinical implication and pathogenic mechanisms of this
long pentraxin are warranted.
4. Conclusions
Although the successful introduction of dialysis in the 1960s
has increased life expectancy in patients with ESRD, the
mortality rate is still unacceptably high, due primary to a
process of inﬂammation-associated accelerated atheroscle-
rosis. The accelerated atherosclerotic process of ESRD may
involveseveralinterrelatedprocesses,suchasoxidativestress,
endothelial dysfunction, vascular calciﬁcation, and inﬂam-
mation. The explosion of new knowledge on the central role
of a dysregulated cytokine and Th system activity has opened
new and exciting opportunities for nephrologists to manage
and prevent CVD and wasting in this diseased patient
group. The use of several traditional and new biomarkers of
inﬂammatoryandcardiovascularriskisofgreatutilityinthis
high-risk population.
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